NLS Pharmaceutics Ltd. -CW25NLSPWPreferred / convertible
13F holders, Q3 2025 (September 30)3holders
1new positions
1sold out
$0.02avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding NLS Pharmaceutics Ltd. -CW25 (NLSPW) in their 13F filings, unchanged from Q2 2025. 1 opened new positions and 1 sold out. The largest holders were Clear Street Group Inc. ($1K), Susquehanna International Group, LLP ($731) and UBS Group AG ($8).
- Company
- NLS Pharmaceutics Ltd. -CW25
- CUSIP
- H57830111
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $8 |
| Exits | 1 | $250 |
All 13F filers, Q2 2025 → Q3 2025: 29,921 shares bought and 12,500 shares sold, net +17,421 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Clear Street Group Inc. | — | — | 57,762 | $1K |
| Susquehanna International Group, LLP | — | Add +180.6% | 45,830 | $731 |
| UBS Group AG | — | New | 424 | $8 |
"% of holder's portfolio" is NLSPW's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. -CW25 the manager owns.